Axim Biotechnologies Inc (AXIM)

[TexasMarvL]

Tarsus Pharmaceuticals (TARS) also in the EyeCare space just raised $100 Million. Their current revenue of $17.5 million seems pretty low to justify such a rich share price. Doesn't seem to add up.

Could the AXIM + Verséa team follow the same path as Tarsus? Surely Verséa Health would not sell their Ophthalmics division right here at the beginning of a growth story would they? Merger of Equals? Could Verséa need cash? I don't know.

It seems like builders would want to sell a product after it is finished, like a house. The Verséa Ophthalmics + AXIM foundation is not even dry yet. The house still needs to be built. Catalina Valencia didn't buy millions of shares of AXIM to sell away for a loss did she?

It just seems like the more LinkedIn posts shared by Verséa Ophthalmics the more people at larger companies in the eyecare space have a reaction to those posts. Including people from Tarsus and Novartis and Bausch and Lomb among others.